Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

Web

Nov. 4, 2019

SCIENTIFIC

Another study has reported that patients experiencing immune-mediated adverse events are more likely to respond to therapy.

https://ascopubs.org/doi/abs/10.1200/JCO.19.00318